Lakefront Biotherapeutics N.V.
LKFT | NASDAQ
$32.28
-$0.05 (-0.15%)
At close: Oct 30, 2026, 4:00 PM ET
$32.28
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Company Profile
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Key Executives
| Name | Position |
|---|---|
| Henry Gosebruch | CEO & Executive Director |
| Aaron L. Cox | Chief Financial Officer |
| Christina Carlson | Chief Operating Officer |
| Tania Philipp | Chief People Officer |
| Ellen Van Der Aar | Head of Development |
| Fred W. Blakeslee | Executive VP & General Counsel |
| Glenn Schulman D. | Head of Investor Relations |
| Jason Treese | Global Head of Quality |
| Jeevan Shetty | Head of Clinical Development Oncology |
| Marieke Vermeersch | Head of Corporate Communication |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
Lakefront Biotherapeutics N.V.
| Country | Belgium |
| IPO Date | May 5, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 452 |
| CEO | Henry O. Gosebruch |
Contact Details
SchaliEnhoevedreef 20 T Mechelen 2800 Belgium
Stock Details
| Ticker Symbol | LKFT |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001421876 |
| CUSIP Number | 36315X101 |
| ISIN Number | US36315X1019 |
| SIC Code | n/a |
Recent News
- 12 days ago / zacks.comLakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?
- 19 days ago / globenewswire.comLakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
- 20 days ago / globenewswire.comAcquisition of Own Shares
- 2 months ago / seekingalpha.comLakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / seekingalpha.comLakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value
- 2 months ago / globenewswire.comLakefront Receives Transparency Notification from Bank of America
- 2 months ago / globenewswire.comU.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
- 3 months ago / globenewswire.comInkoop van eigen aandelen
- 4 months ago / globenewswire.comLakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofi
- 4 months ago / globenewswire.comLakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Add to Watchlist
Select watchlists to add or remove LKFT